Nelson Advisors 10 Key Reflections from HLTH Europe 2026

Nelson Advisors
4 hours ago
8 min read

Five thousand leaders, one in three of them holding an executive title, descended on the RAI Amsterdam from 15th to 18th June 2026 for HLTH Europe. The call to action this year was "Step Outside", a deliberate nudge to leave the comfort zone, look at familiar problems from unfamiliar angles, and find energy in collaboration across boundaries.

For those of us who spend our days on the deal side of digital health, the phrase turned out to be an unusually accurate description of where the market is heading. The walls between sub-sectors, between strategics & start-ups and between European and global capital are coming down.

Here are ten reflections from the Nelson Advisors team on what HLTH Europe 2026 tells us about M&A, partnerships and investment for the year ahead.

1. AI has crossed from narrative to numbers and that is reshaping the buy side

For three years, "AI" was a slide that raised a round. At HLTH Europe 2026 the mood was different. The dedicated AI @ HLTH zone and the interoperability programming were packed, but the questions from the stage and the corridors were sharper: where is the measurable clinical outcome, where is the reimbursement and where is the gross margin once you strip out the compute bill. That maturity matters enormously for dealmaking. When buyers stop paying for promise and start paying for proven workflow integration, the market bifurcates.

A small number of Healthcare AI companies with validated, deployed and revenue-generating products become highly contested acquisition targets, while a long tail of point solutions face a much harder funding road. Expect that gap to drive consolidation: the strongest platforms will acquire capability, data and talent, and the weakest will become acqui-hires or quietly wind down.

For founders, the lesson from Amsterdam is blunt, defensible data assets and demonstrable ROI are now the currency that determines whether you are a buyer or are bought.

2. Interoperability is the quiet engine of Health IT M&A

The headline sessions belonged to AI, but the connective tissue underneath every conversation was interoperability. The recurring framing, AI as the bridge that cleans messy data, translates formats and finally helps systems speak the same language, points to where a great deal of capital is about to flow. Health IT infrastructure is unglamorous, but it is sticky, recurring revenue and increasingly mandated by policy. That combination makes it a magnet for both strategic acquirers and private equity.

We expect continued roll-up activity around data integration engines, FHIR-native platforms, clinical data warehouses and the middleware that sits between electronic health records and the new wave of AI applications.

The European Health Data Space gives this thesis a regulatory tailwind: every provider and payer in Europe will need to move, standardise and share data at scale, and very few will build that capability in-house. Buyers who control the pipes will control the value, and that is a structurally attractive place to deploy capital.

3. Strategic acquirers are back in the room

One of the clearest signals from HLTH Europe 2026 was the visible presence of corporate development teams from payers, providers, pharma and the larger HealthTech platforms. The Health Transformation Summit, bringing together more than 200 policymakers, provider and payer CEOs and innovators, was as much a private dealmaking forum as a policy debate. After two years in which financial sponsors dominated activity by default, strategics are leaning back in.

Their motivation is partly defensive: incumbents cannot afford to let AI-native challengers capture the workflow layer between them and their patients or members. It is also partly offensive: acquiring a proven digital capability is faster and more certain than building one.

For sellers, a re-engaged strategic buyer universe is the single most important driver of competitive tension in a process, and therefore of valuation. The presence of these teams in Amsterdam suggests 2026 and 2027 will see more strategic-led transactions than the recent past.

4. "Step Outside" is really a story about convergence

The conference theme was about leaving your comfort zone, and the deal implication is convergence. The most interesting partnership conversations at HLTH Europe were not within sub-sectors but across them: pharma companies partnering with Healthcare AI firms on diagnostics and patient identification; retail and consumer brands moving into clinically validated care; medtech and Health IT companies fusing devices with software and data services.

Convergence creates a rich environment for both partnerships and M&A because the strategic logic, acquiring a capability you cannot credibly build, is so clear. It also means buyers and targets increasingly come from outside the obvious peer set.

A consumer technology company buying a remote monitoring business, or a pharma services group acquiring a patient-engagement platform, will look less surprising by the end of the year. Advisors and founders who define their competitive and acquirer landscape too narrowly will miss the most valuable counterparties.

5. Consumer HealthTech is growing up, and trust is the asset being bought

Consumer HealthTech arrived at HLTH Europe in a more mature form than in previous years. The direct-to-consumer wellness narrative has given way to a focus on clinical validation, regulatory standing and, crucially, reimbursement pathways. That shift changes the M&A logic.

The companies winning attention are those that have converted consumer reach into clinically credible, ideally reimbursable, propositions, in areas such as women's health, metabolic health, mental health and chronic disease management. For acquirers, the prize in this segment is twofold: distribution and trust.

Building a consumer brand and earning patient trust is slow and expensive, which makes acquisition an attractive shortcut for incumbents seeking a direct relationship with patients. We expect continued pairing of capital-rich strategics with consumer-facing platforms that have the engagement but lack the balance sheet to scale clinically. Valuation in this segment will increasingly reward evidence and retention over raw user growth.

6. Healthcare cybersecurity has moved from cost centre to boardroom priority

If one theme has graduated fastest from niche to mainstream, it is Healthcare Cybersecurity. The combination of relentless ransomware activity against hospitals, the expansion of connected medical devices and the tightening European regulatory regime, NIS2 and related directives, has pushed security to the top of the provider and payer agenda. That is showing up in budgets and, increasingly, in deal flow. Healthcare-specific security companies, identity and access management for clinical environments, medical device security and third-party risk management are all attracting investor attention.

The investment case is compelling: regulatory mandates create non-discretionary demand, healthcare's threat surface is expanding, and the cost of a breach, in both fines and patient safety, is rising.

We anticipate both venture and growth capital flowing into the sector and a wave of consolidation as broader security platforms acquire healthcare-specific expertise to serve a vertical that can no longer be treated as generic enterprise IT.

7. Capital is disciplined, not absent and the quality bar is high

Anyone hoping HLTH Europe would signal a return to 2021-style exuberance left disappointed, and rightly so. The investment tone was disciplined. Capital is available, there is meaningful dry powder across European and global healthcare funds, but it is being deployed selectively and at valuations that reflect a reset from the peak.

The practical consequences are visible across the market: well-run businesses with strong unit economics are raising and trading at healthy multiples, while companies that scaled on cheap capital without a path to profitability face down rounds, bridge financings, structured deals or sale processes conducted from a position of weakness.

Secondary transactions and continuation vehicles are increasingly part of the toolkit as funds manage liquidity for limited partners. The message for founders is consistent with everything else heard in Amsterdam: efficient growth, clear margins and a credible route to profitability are what unlock both capital and optionality.

Story alone no longer clears the bar.

8. European regulation is both friction and moat

Few topics divided opinion at HLTH Europe more than regulation. The European Health Data Space, the AI Act and the Medical Device Regulation are real costs and real complexity, and plenty of founders voiced frustration at the pace and expense of compliance. But the deal-side reading is more nuanced. Regulation that is hard to navigate is also a barrier to entry, and barriers to entry create defensibility.

Companies that have done the hard work of clinical validation, CE marking, AI Act conformity and data-governance compliance hold an asset that is difficult and slow to replicate.

That defensibility is precisely what strategic acquirers pay premiums for. Regulation is also spawning its own investable category, the reg-tech, compliance and quality-management tooling that healthcare organisations need to keep pace.

For investors willing to underwrite the complexity, Europe's regulatory environment is not only friction; it is the foundation of durable competitive advantage and a driver of M&A in the compliance layer itself.

9. Partnerships are the on-ramp to acquisition

Perhaps the most practically useful reflection from HLTH Europe 2026 is how much dealmaking is now sequenced through partnership before it reaches acquisition. In an environment of valuation uncertainty and integration risk, large strategics are increasingly reluctant to make a cold acquisition of an unproven asset. Instead they are using commercial partnerships, pilots, co-development agreements and minority investments as a way to de-risk, to test the technology, the team and the cultural fit before committing to a full purchase. For founders this is a double-edged dynamic.

A well-structured partnership can be the most efficient path to a premium exit, providing validation and a warm relationship with a natural acquirer. But partnerships can also lock a company into a single counterparty, suppress competitive tension and quietly transfer know-how.

The companies that navigate this best treat partnerships strategically, building several relationships, protecting their data and IP, and keeping their options open so that any eventual sale is competitive rather than captive.

10. The exit outlook favours the prepared

Finally, what does all of this mean for liquidity? The IPO window for European digital health remains cautious, and few expect it to swing fully open in the near term. That places the weight of exits on two channels: strategic acquirers, who as noted are re-engaging and private equity, which has both capital to deploy and a growing appetite for healthcare technology roll-ups built around recurring revenue and mission-critical software.

Cross-border activity is a defining feature of this market, European assets are attractive to North American and increasingly Asian buyers and European strategics are looking abroad for capability.

The overarching message from Amsterdam is that exit value will accrue disproportionately to the prepared: companies with clean data rooms, validated outcomes, strong security and compliance postures, efficient growth and a clearly articulated strategic fit for a defined set of acquirers.

The market rewards readiness, and readiness takes time to build.

Final Thoughts

HLTH Europe 2026 captured a sector that has grown up. The exuberance has gone, replaced by a harder-edged focus on outcomes, economics and defensibility and that is a healthier foundation for dealmaking than the froth that preceded it.

AI is the catalyst, interoperability is the infrastructure, regulation is the moat, and convergence is the strategic story tying it all together.

For founders, investors and corporate development teams, the firms that "step outside" their comfort zone, looking beyond their immediate sub-sector for partners, acquirers and capital, will be the ones who create and capture value over the next cycle.

The deals that define European digital health in 2026 and 2027 were, in many cases, first sketched in the corridors of the RAI.

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech